Aastrom Biosciences News

If you think the markets are going to become more volatile in the near future, you may be interested in this list.

ASTM has made significant progress during the past 12 months and is now in a much stronger position to execute on clinical programs while anticipating an IRB approval to begin clinical trial of their autologous cell therapies, ixmyelocel-T. Critical Limb Ischemia has a potentially enormous market opportunity.

The stock last traded at $2.10, up from its previous close of $1.97. Separately, analysts at WBB Securities upgraded shares of Aastrom Biosciences from a "sell" rating to a "hold" rating in a research note to investors on Tuesday, December 6th.

Shares of Aastrom Biosciences have declined nearly 30% over the past two months, despite what we view as very positive results from the company's phase 2b RESTORE-CLI trial.

According to GuruFocus Insider Data , the largest CFO sells during the past week were: Pandora Media, Aastrom Biosciences In.c, Meritor and PSS World Medical Inc.